225 related articles for article (PubMed ID: 37709932)
1. Predicting lung adenocarcinoma prognosis, immune escape, and pharmacomic profile from arginine and proline-related genes.
Wang Z; Zhang J; Shi S; Ma H; Wang D; Zuo C; Zhang Q; Lian C
Sci Rep; 2023 Sep; 13(1):15198. PubMed ID: 37709932
[TBL] [Abstract][Full Text] [Related]
2. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
3. A Novel Risk Model Based on Autophagy Pathway Related Genes for Survival Prediction in Lung Adenocarcinoma.
Zhang F; Xie S; Zhang Z; Zhao H; Zhao Z; Sun H; Zheng J
Med Sci Monit; 2020 Sep; 26():e924710. PubMed ID: 32873769
[TBL] [Abstract][Full Text] [Related]
4. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
5. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
Li F; Niu Y; Zhao W; Yan C; Qi Y
Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
[TBL] [Abstract][Full Text] [Related]
6. Subtype classification based on t cell proliferation-related regulator genes and risk model for predicting outcomes of lung adenocarcinoma.
Yang Q; Zhu W; Gong H
Front Immunol; 2023; 14():1148483. PubMed ID: 37077919
[TBL] [Abstract][Full Text] [Related]
7. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of a novel signature incorporating lipid metabolism and immune-related genes for assessing prognosis and immune landscape in lung adenocarcinoma.
Wang Y; Xu J; Fang Y; Gu J; Zhao F; Tang Y; Xu R; Zhang B; Wu J; Fang Z; Li Y
Front Immunol; 2022; 13():950001. PubMed ID: 36091041
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
10. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma.
Li S; Wang W; Yu H; Zhang S; Bi W; Sun S; Hong B; Fang Z; Chen X
BMC Cancer; 2023 Nov; 23(1):1115. PubMed ID: 37974107
[TBL] [Abstract][Full Text] [Related]
11. Identification of four metabolic subtypes and key prognostic markers in lung adenocarcinoma based on glycolytic and glutaminolytic pathways.
Zhang J; Wang X; Song C; Li Q
BMC Cancer; 2023 Feb; 23(1):152. PubMed ID: 36782138
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
13. Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes.
Duan G; Huang C; Zhao J; Zhang Y; Zhao W; Dai H
Sci Rep; 2023 Nov; 13(1):20930. PubMed ID: 38017020
[TBL] [Abstract][Full Text] [Related]
14. Development of the prognostic value in lung adenocarcinoma based on anoikis-related genes and initial experimental validation.
Guo W; Zhao G; Liu S; Deng T; Zhang G; Zhang B
J Gene Med; 2023 Sep; 25(9):e3534. PubMed ID: 37259225
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis reveals the potential value of inflammatory response genes in the prognosis, immunity, and drug sensitivity of lung adenocarcinoma.
Song C; Pan S; Li D; Hao B; Lu Z; Lai K; Li N; Geng Q
BMC Med Genomics; 2022 Sep; 15(1):198. PubMed ID: 36117156
[TBL] [Abstract][Full Text] [Related]
16. Nonnegative matrix factorization-based bioinformatics analysis reveals that TPX2 and SELENBP1 are two predictors of the inner sub-consensuses of lung adenocarcinoma.
Wang H; Wang X; Xu L; Cao H; Zhang J
Cancer Med; 2021 Dec; 10(24):9058-9077. PubMed ID: 34734491
[TBL] [Abstract][Full Text] [Related]
17. Immune- and Stemness-Related Genes Revealed by Comprehensive Analysis and Validation for Cancer Immunity and Prognosis and Its Nomogram in Lung Adenocarcinoma.
Chen M; Wang X; Wang W; Gui X; Li Z
Front Immunol; 2022; 13():829057. PubMed ID: 35833114
[TBL] [Abstract][Full Text] [Related]
18. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
19. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
Cao K; Ling X; Jiang X; Ma J; Zhu J
Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]